Fine Organic Industries:
₹75 Cr Revenue. 33x P/E. Building a US
Factory While Profit Margins Crater.
They make fancy additives for fancy products. Coca-Cola drinks them. Britannia bakes with them. But somehow, Q3 profits crashed 10.6% while revenue barely grew. And now they’re burning ₹700 crores on a US expansion. Because why play it safe?
The Specialty Additives Unicorn That Trades Like a Fantasy Stock
- 52-Week High / Low₹5,494 / ₹3,355
- TTM Revenue₹2,347 Cr
- TTM PAT₹391.5 Cr
- Full-Year EPS (TTM)₹129.38
- 9-Month (Apr-Dec) EPS₹96.84
- Book Value₹808
- Price to Book5.36x
- Dividend Yield0.25%
- Debt / Equity0.01x
- Promoter Holding75%
Where They Make the Gunk That Makes Your Shampoo Shiny
Let’s talk about Fine Organic Industries. Not a household name — unless your household is Coca-Cola, Britannia, Asian Paints, or Berger Paints. Then you already own their products. They just don’t tell you about it. It’s like that friend who does all the behind-the-scenes work and never gets credited.
Fine makes oleochemical-based additives. Which sounds like corporate word salad, but basically: they take vegetable oils, mix them with fancy chemistry, and sell the result to food companies (as emulsifiers), plastic makers (as slip agents and anti-fogging compounds), cosmetics brands (as emollients), and paint makers (as wetting agents). It’s boring chemistry that makes consumer products work better. No AI. No blockchain. No “platform.” Just 55+ years of manufacturing chops and 600+ products served to 890+ direct customers across 80+ countries.
Founded in 1970, part of the Fine Organics Group. 75% promoted by the Shah family. 3 manufacturing plants in Maharashtra (Dombivli, Badlapur, Ambernath, Patalganga). Plus warehouses in the USA and Europe. Revenue touched ₹2,347 crores in TTM. Profit margins have been the real drama — operating margins compressed from 27% (FY23) to 20% (TTM) because raw material inflation hit harder than their pricing power. And now, with ₹700–750 crores set to burn on a US facility (plus a land acquisition in South Carolina), the plot thickens: either they’re about to unlock 3x growth in the next 3–5 years, or they’re about to become a very expensive finance experiment.
Oleochemicals for Everything. Margins for Nothing.
Fine Organic runs one of those B2B specialty chemical businesses where the real money sits in long-term customer relationships, proprietary formulations, and execution discipline. Here’s the playbook: raw material procurement (vegetable oils, derivatives), in-house R&D (25 scientists, 33 technicians), manufacturing across 4 plants, quality control (global certifications), distribution to 890+ direct customers, and inventory management at 100+ days payables outstanding.
Revenue split: 43% domestic, 57% exports. That’s right — more than half comes from shipping out. Customers are blue-chip: Coca-Cola, Britannia, Asian Paints, Parle, Pidilite, Berger Paints. No single customer does more than 5% of sales. And that’s beautiful — until tariffs hit or shipping costs spike or a competitor in China launches at 30% cheaper.
Product portfolio: 600+ SKUs across 5 main buckets. Polymer additives (lubricants, slip agents, anti-fogging), food additives (emulsifiers, anti-fungals, clouding agents), feed nutrition (probiotics, anti-fungals), cosmetics & pharma (emollients, green surfactants), and coatings (wetting agents, dispersants). The diversification is real. But the margin compression over 3 years is also real.
Q3 FY26: The Numbers Don’t Lie (They Just Look Sad)
Result type: Quarterly Results | Q3 FY26 EPS: ₹24.11 | Annualised EPS (Q3×4): ₹96.44 | 9-Month EPS (Apr-Dec): ₹96.84
Source table
| Metric (₹ Cr) | Q3 FY26 Dec 2025 |
Q3 FY25 Dec 2024 |
Q2 FY26 Sep 2025 |
YoY % | QoQ % |
|---|---|---|---|---|---|
| Revenue | 555 | 517 | 597 | +7.3% | -7.1% |
| Operating Profit | 94 | 103 | 134 | -8.7% | -29.9% |
| OPM % | 17% | 20% | 22% | -300 bps | -500 bps |
| PAT | 74 | 83 | 109 | -10.6% | -32.2% |
| EPS (₹) | 24.11 | 26.97 | 35.40 | -10.6% | -31.9% |
What’s This Chemical Company Actually Worth?
Method 1: P/E Based
9-Month EPS (Apr-Dec) = ₹96.84. Annualised FY26 EPS (est.) = ₹128–132 (conservative, given Q3 margins). Sector median P/E = 26.6x. Fair premium for margins and scale: 0.9x–1.1x sector (because margins are compressing). Fair P/E band: 24x–29x.
Range: ₹3,072 – ₹3,828
Method 2: EV/EBITDA Based
9M FY26 EBITDA (operating profit + depreciation) = ₹258.4 Cr. TTM EBITDA ≈ ₹468 Cr. Current EV (Market Cap – Net Cash) = ₹12,138 Cr (given ₹1,050 crore cash, ₹16.4 Cr debt = net positive). EV/EBITDA = 25.9x. Specialty chemicals trade at 15x–22x. Fine is expensive here too.
EV range (18x–23x): ₹8,424 Cr – ₹10,764 Cr → Per share (net cash ₹1,034 Cr):
Range: ₹3,150 – ₹3,750
Method 3: DCF Based
Base FCF: ₹204 Cr (9M operating CF). Annualised: ~₹270–280 Cr. Growth assumption: 8–10% for 5 years (revenue growth). Terminal growth: 3%. WACC: 10.5% (debt-free, low risk).
→ Terminal Value (3% growth / 7.5% cap rate): ~₹12,000 Cr
→ Total EV: ~₹13,350 Cr (includes ₹1,034 Cr net cash)
Range: ₹3,100 – ₹3,850
Building a US Factory While Margins Burn
🏭 The Big Play: US Manufacturing Facility
Fine Organic acquired 159.92 acres in South Carolina in July 2025. Plans a manufacturing facility with capex expected to be higher than the domestic expansion (₹700–750 Cr). Expected to be operational in 3–5 years. ICRA flagged execution risk: new geography, stringent regulatory environment, tariff headwinds (50% US tariffs on Indian imports pending trade deal). Management says it’s necessary for long-term growth. The market says: “prove it.”
⚠️ The Ugly Numbers
- • Q3 PAT down 10.6% YoY despite 7.3% revenue growth
- • Operating margin compressed to 17% from 22% (Q2)
- • Raw material inflation eating lunch (vegetable oils volatile)
- • US tariffs creating export uncertainty (57% of sales)
- • Working capital Days Payable extended to 100+ days
✅ The Silver Linings
- • ₹1,050 crore in cash — can fund US expansion
- • Debt-free (₹16.4 Cr only, 0.01x D/E)
- • ICRA rating: AA (Stable) — confidence in long-term ability
- • ROCE 26.4% — capital efficiency is fine (before capex drag)
- • Diversified customer base — no concentration risk
Is the Fort Standing? Yes. Is It Being Drained? Also Yes.
Source table
| Item (₹ Cr) | Mar 2024 | Mar 2025 | Sep 2025 | Latest |
|---|---|---|---|---|
| Total Assets | 2,108 | 2,511 | 2,660 | 2,660 |
| Net Worth (Eq + Reserves) | 1,910 | 2,295 | 2,477 | 2,477 |
| Borrowings | 4 | 3 | 16 | 16 |
| Other Liabilities | 194 | 213 | 167 | 167 |
| Total Liabilities | 2,108 | 2,511 | 2,660 | 2,660 |
Net worth jumped from ₹2,295 Cr (Mar’25) to ₹2,477 Cr (Sep’25) — but that’s organic growth from retained earnings. The ₹700+ crore capex starts now. Watch for net worth stagnation or leverage increase in FY27 filings.
Borrowings: ₹16 Cr. That’s a rounding error. Debt-to-equity: 0.01x. The company is a fortress. But a fortress with a ₹700 crore expansion plan eating cash.
Current capex: domestic ₹700–750 Cr + US facility (higher). Equity + retained earnings funding it. If returns on capex disappoint, re-rates get ugly.
Generating Cash Today. Burning It Tomorrow.
Source table
| Cash Flow (₹ Cr) | FY24 | FY25 | 9M FY26 |
|---|---|---|---|
| Operating CF | +635 | +204 | N/A* |
| Investing CF | -396 | -676 | Rising |
| Financing CF | -59 | -34 | TBD |
| Net Cash Flow | +180 | -506 | TBD |
Great Ratios. Terrible Timing.
Revenue Up. Profits Down. Margin Margin On The Wall.
Source table
| Metric (₹ Cr) | FY24 | FY25 | TTM |
|---|---|---|---|
| Revenue | 2,123 | 2,269 | 2,347 |
| Operating Profit | 532 | 512 | 470 |
| OPM % | 25% | 23% | 20% |
| PAT | 412 | 410 | 391.5 |
| EPS (₹) | 134.34 | 133.89 | 129.38 |
This is the story of a company that’s growing top-line (5% CAGR), but profit is stagnating because costs are rising faster. Raw materials (vegetable oils, derivatives) are the culprit. Pricing power exists, but it’s laggy. And now they’re adding ₹700 crore capex debt to a lower-profit base. Math doesn’t favour them short-term.
Fine Organic vs Specialty Chemicals Peers: The Richest Kid in Class
Source table
| Company | CMP Rs | P/E | MCap Rs.Cr | ROCE % | OPM % | Sales 12M Rs.Cr |
|---|---|---|---|---|---|---|
| Fine Organic | 4,330 | 33.94x | 13,284 | 26.4% | 20% | 2,347 |
| Pidilite Inds. | 1,390 | 61.10x | 141,417 | 29.84% | 23.43% | 14,159 |
| Deepak Nitrite | 1,481 | 37.29x | 20,216 | 16.28% | 11.59% | 7,946 |
| Gujarat Fluoroch | 3,182 | 52.45x | 34,977 | 9.89% | 26.57% | 4,852 |
| BASF India | 3,482 | 38.89x | 15,022 | 18.02% | 4.13% | 14,721 |
Fine Organic at 33.94x P/E sits in the middle of the pack. Not the most expensive (that’s Pidilite at 61x, but they’re also 6x larger and growing faster). Not the cheapest (that’s Deepak Nitrite at 37x, but they have lower ROCE). The real issue: Fine is priced for 3–5 year US expansion success. Current results don’t justify it yet.
The Shahs Own It All. And They’re Betting Big.
- Promoters (Shah Family)75.00%
- DIIs (incl. Axis MF 4.06%)11.80%
- FIIs4.43%
- Public8.78%
Pledge: 0.00%. Shareholder base: 93,942 retail investors (down from 116,910 in Mar 2023). Retail is exiting slightly. Smart money is cautious.
Promoters: The Shah Family (75%)
Founded in 1970. Tushar Ramesh Shah (16.26%), Jayen Ramesh Shah (15.70%), Bimal Mukesh Shah (10.44%), and others — classic Mumbai Gujarati family business structure. No pledges. Skin in the game. They’re bankrolling the US expansion with their own cash. That’s vote of confidence or existential desperation — hard to tell which.
Institutional Holding: Axis MF Leading
Axis Mutual Fund holds 4.06% — they’re the biggest institutional holder. Nippon Life India at 2.56%. SBI Nifty SmallCap at 2.30%. Modest institutional confidence. The fact that FII holding is low (4.43%) suggests foreign capital doesn’t see the US expansion as a slam dunk.
The Good. The Bad. The Audacious.
✅ The Solid Ground
- ✓ ICRA rating: AA (Stable) — strong credit profile
- ✓ No major audit qualifications in recent years
- ✓ 0% promoter pledge — full alignment
- ✓ Dividend policy consistent (0.25% yield, but ₹11 final dividend in FY25)
- ✓ Regular quarterly concalls and investor engagement
- ✓ 33 scientists + technicians in R&D — innovation backbone
- ✓ Fire incident (Jan 2024) handled, production resumed by Nov 2024
⚠️ The Wildcard Risks
- ⚠ ₹700–750 crore domestic expansion + US facility = execution risk
- ⚠ New geography (USA) with stringent regulatory environment
- ⚠ 50% US tariffs on Indian imports — pending trade deal (as of Feb 2026)
- ⚠ Margin compression from raw material inflation: unresolved
- ⚠ No clear CEO/MD change mentioned (operational continuity risk)
- ⚠ 93,942 retail investors (down 19% from Mar 2023) — retail fleeing
Oleochemicals: Where Boring Meets Brave (And Sometimes Stupid)
The global specialty chemicals market is a ₹2+ trillion pie. India’s piece: ₹200–250 billion. Growth rate: 4–5% annually. Fine Organic’s domestic market is growing at 3–4%, exports at higher rates (but FX volatility is real). The industry drivers: rising demand from food emulsifiers (packaged food boom), polymer additives (plastics recycling standards getting stricter, demand for quality additives rising), cosmetics (India’s beauty market growing 10%+ annually), and coatings (infrastructure capex driving paint demand).
🔴 The Tariff Sword: Hanging Over Exports
57% of Fine’s sales are exports. US tariffs at 50% on Indian imports. If tariffs stick post-trade negotiations, exports to the USA become uncompetitive — a key market for oleochemical additives. Fine’s US factory bet is essentially: “we’ll move production there to avoid tariffs.” But if tariffs disappear, the capex was wasted. Timing is everything.
✅ Raw Material Cost Normalization
Vegetable oil prices (palm, soybean) have volatile cycles. Current cycle is high. If prices normalize in FY27–FY28, margins could recover 200–300 basis points without price increases. Management is banking on this. Investors are betting against it.
💡 Green Additives Tailwind
Shift from synthetic to oleochemical additives is real. Regulators favour bio-based, non-toxic formulations. Fine is well-positioned here. But so are competitors in Malaysia, Indonesia, and China. The real question: can Fine’s R&D and customer relationships outweigh their higher cost structure? Unclear.
📈 India’s Infrastructure Capex Driving Coatings
Road construction, urban development, industrial parks — all need paint and coatings. This drives demand for coating additives (dispersants, wetting agents). Fine supplies this. Tailwind visible through FY26–FY27, potentially.
Competitive landscape: Fine competes with Pidilite (larger, diversified, better margins), Deepak Nitrite (focused on chemicals, lower ROCE), Gujarat Fluorochemicals (different end-markets), and global majors like BASF, Clariant, Eastman. The market is mature. Consolidation possible. Fine’s bet is on scale (USA expansion) and customer stickiness (decades-long relationships). Fair bet, but risky.
Macro context: India’s specialty chemicals exports facing headwinds from tariffs and Chinese competition. But domestic demand (food, paint, cosmetics, polymers) remains healthy. The question is: does Fine grow faster than the market through US expansion, or does it become another mid-size Indian chemical company growing at single digits?
The Chemical Verdict
Fine Organic is a paradox wrapped in an expensive valuation. 26.4% ROCE. Debt-free. ₹1,050 crore cash. 600+ products. 890+ customers. 55+ years in business. And yet, margins are compressing, profits are stagnating, and they’re about to burn ₹700+ crores on an unproven US expansion. The stock trades at 33.94x P/E — pricing in 3–5 year success. Current results say: not yet.
Q3 FY26 Execution: Revenue grew 7.3% YoY to ₹555 crore. But PAT fell 10.6%. Operating margin crashed to 17% from 22% in just one quarter. This is not the sign of a company in control. Raw material inflation is crushing, pricing power is limited, and the US expansion hasn’t even started yet.
The US Expansion Bet: ₹700–750 crore domestic facility + higher capex for USA. Expected to come online in 3–5 years. If it delivers 30–40% of current company revenues, the math rewrites itself. If it underperforms, shareholders funded a very expensive mistake. Management is betting on tariff avoidance (US tariffs at 50%) and export growth. Both are real risks.
Historical context: Over 5 years, Fine’s revenue CAGR is 16.9%, but stock CAGR is only 12.7%. Over 3 years, stock CAGR is 0.06% (basically flat). This is a business that’s grown top-line but not bottom-line, and hasn’t rewarded shareholders proportionally. The ₹700+ crore capex is a bet that the next 5 years will be different.
Margin compression is the real issue: Operating margin fell from 27% (FY23) to 20% (TTM). That’s 700 basis points of erosion. The cause: raw material cost inflation that the company has only partially passed on. Until this reverses or pricing power improves, profitability will remain under pressure. The US expansion adds no relief — it adds complexity.
✓ Strengths
- 26.4% ROCE — efficient capital deployment
- Debt-free with ₹1,050 crore cash — fortress balance sheet
- 600+ products across 5 segments — diversification
- 890+ direct customers, 80+ countries — global reach
- 55+ year track record, AA rating — credibility
- R&D capability (58+ scientists) — innovation pipeline
✗ Weaknesses
- Operating margin compressed 700 bps in 3 years
- Profit stagnation despite revenue growth
- Vegetable oil price volatility = profit volatility
- 57% exports exposed to FX and tariff risks
- P/E 33.94x — premium valuation, results don’t justify
- Retail shareholder base declining (down 19% in 2 years)
→ Opportunities
- US expansion avoids 50% tariffs (if expansion succeeds)
- Raw material cost normalization could recover 200–300 bps
- Green additives tailwind from regulatory shift
- India infrastructure capex driving coatings demand
- Domestic market penetration still possible (43% of sales only)
- Potential acquisition target if execution falters
⚡ Threats
- US tariffs could make exports uncompetitive (despite factory)
- US expansion execution risk (new geography, regulations)
- Chinese competitors with lower cost structures
- Continued raw material inflation eroding margins
- Shallow institutional support (FIIs only 4.43%)
- Capex disappointment = multiple compression risk
Fine Organic is a company in transition betting big on future scale.
The underlying business is solid. Customers are blue-chip. Margins are compressing, yes, but the company has ₹1,050 crore cash and zero debt to fund its way through the expansion cycle. The question is: will US expansion deliver 3x revenue growth and restore margins, or will it be a capex sink that dilutes ROCE further? The market is pricing in success. Current results hint at caution.
Fair value range of ₹3,100–₹3,850 assumes the expansion delivers meaningful returns by FY29–FY30. CMP of ₹4,330 assumes success is already priced in. At current multiples, downside protection is thin. Upside exists only if capex executes perfectly and margins recover. That’s a bet, not a buy.